0001104659-23-009974.txt : 20230202 0001104659-23-009974.hdr.sgml : 20230202 20230202171041 ACCESSION NUMBER: 0001104659-23-009974 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230131 FILED AS OF DATE: 20230202 DATE AS OF CHANGE: 20230202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harris Matthew Scott CENTRAL INDEX KEY: 0001787762 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 23582127 MAIL ADDRESS: STREET 1: C/O ALTIMMUNE, INC. STREET 2: 910 CLOPPER ROAD, SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Altimmune, Inc. CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 910 CLOPPER ROAD STREET 2: SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 2406541450 MAIL ADDRESS: STREET 1: 910 CLOPPER ROAD STREET 2: SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 FORMER COMPANY: FORMER CONFORMED NAME: PHARMATHENE, INC DATE OF NAME CHANGE: 20071016 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 4 1 tm235311-3_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2023-01-31 0 0001326190 Altimmune, Inc. ALT 0001787762 Harris Matthew Scott C/O ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S GAITHERSBURG MD 20878 0 1 0 0 Chief Medical Officer Common Stock, par value $0.0001 2023-01-31 4 A 0 1296 10.2085 A 13917 D Common Stock, par value $0.0001 2023-02-01 4 M 0 6166 0 A 20083 D Common Stock, par value $0.0001 2023-02-01 4 F 0 2183 13.78 D 17900 D Restricted Stock Units 2023-02-01 4 M 0 6166 0.00 D Common Stock, par value $0.0001 6166 12332 D These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2022 through January 31, 2023. In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2022. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. /s/ Richard Eisenstadt, as Attorney-in-Fact 2023-02-02